Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Sickle Cell Disease
Interventions
DRUG

Placebo

Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.

DRUG

Zoledronic Acid

Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Virginia Commonwealth University

OTHER

NCT00639392 - Phase 1 Study of Zoledronic Acid in Sickle Cell Disease | Biotech Hunter | Biotech Hunter